On June 1, 2022 Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, reported the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022 (Press release, Beyond Cancer, JUN 1, 2022, View Source [SID1234615361]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to appoint Dr. Monson as our Chief Medical Officer at this important point in the short history of Beyond Cancer. In this role, he will oversee our first-in-human trial in Israel, which is expected to begin by mid-2022, as well as spearhead our efforts to begin clinical trials in the U.S.," commented Selena Chaisson, CEO of Beyond Cancer. "Dr. Monson’s contributions to the field of oncology and to patients at a prestigious clinical care and research focused institution will be an invaluable resource for Beyond Cancer as we continue our mission of bringing ultra-high concentration nitric oxide (UNO) therapy to solid tumor patients."
"The concept of nitric oxide utilized at ultra-high concentrations to impart an immune response with potentially minimal side effects is an exciting prospect. The preclinical data presented by Beyond Cancer to date have shown UNO therapy has the potential to be a very important treatment option for cancer patients and their caregivers," commented Dr. Monson on his appointment as Chief Medical Officer. "I am excited to join Beyond Cancer as we look to begin enrolling patients in a first-in-human clinical trial."
Dr. Monson, a founding partner of cCARE in 2008, oversaw its growth into the largest private practice oncology group in the state of California with a focus on research and excellence in clinical care. In April 2022, cCARE merged with Integrated Oncology Network (ION) resulting in a nationwide oncology and healthcare management group, with a presence in 57 oncology centers across 14 states. He has previously held staff positions at the City of Hope National Medical Center, Valley Radiotherapy Associates, and 21st Century Oncology. In addition, Dr. Monson is a member of the American College of Radiology and the American Society of Therapeutic Radiology & Oncology.
Dr. Monson earned his M.D. from Stanford University School of Medicine and completed his radiation oncology residency at the Joint Center for Radiation Therapy at Harvard Medical School. During his residency, he received an M.P.H from Harvard School of Public Health.
About Nitric Oxide (NO)
Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries, and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate and adaptive immune system response and in vitro studies suggest that NO possesses broad-spectrum antimicrobial activity and anticancer properties.